Morphine formulations
AssigneeFresenius Kabi Deutschland GmbH
InventorsAlain CUINE, Didier HOARAU, Pauline ROMAIN
Life of this patent
Estimating the term…
Abstract
Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
Claims20
A pharmaceutical formulation comprising:
- (a) morphine, or a salt thereof, or a hydrate thereof;
- (b) an isotonic agent;
- (c) a buffering agent with anti-oxidative properties;
- (d) a chelating agent;
- (e) a complement to a chelating agent;
- and
- (f) water,
- wherein the formulation has a pH of from about 2.5 to about 6.5.
A pharmaceutical formulation comprising:
- (a) morphine, or a salt thereof, or a hydrate thereof;
- (b) an isotonic agent;
- (c) a buffering agent with anti-oxidative properties;
- (d) a chelating agent;
- (e) a complement to a chelating agent;
- and
- (f) water,
- wherein the formulation comprises not more than about 1.5% total impurities following storage at 25° C./60% Relative Humidity for at least 12 months.
A method of reducing adverse effects of an injectable morphine pharmaceutical formulation comprising a chelating agent, the method comprising the addition of a complement to the chelating agent to the injectable morphine pharmaceutical formulation.
Dependencies are inferred from the claim text.